Small molecule HIV entry inhibitors: Part I. Chemokine receptor antagonists: 2004 – 2010

Bibliography

• AIDS Epidemic Update. 2009. Available from: http://www.unaids.org [Cited 15 April 2010]
   Google Scholar
• Dayam R, Gundla R, Al-Mawsawi LQ, Neamati N. HIV-1 integrase inhibitors: 2005-2006 update. Med Res Rev 2008;28:118-54
   PubMed Web of Science ®Google Scholar
• Piscitelli SC, Flexner C, Minor JR, Drug interactions in patients infected with human immunodeficiency virus. Clin Infect Dis 1996;23:685-93
   PubMed Web of Science ®Google Scholar
• Kwong PD, Wyatt R, Sattentau QJ, Oligomeric modeling and electrostatic analysis of the gp120 envelope glycoprotein of human immunodeficiency virus. J Virol 2000;74:1961-72
   PubMed Web of Science ®Google Scholar
• Weiss CD, Levy JA, White JM. Oligomeric organization of gp120 on infectious human immunodeficiency virus type 1 particles. J Virol 1990;64:5674-77
   PubMedGoogle Scholar
• Chan DC, Fass D, Berger JM, Kim PS. Core structure of gp41 from the HIV envelope glycoprotein. Cell 1997;89:263-73
   PubMed Web of Science ®Google Scholar
• Dorr P, Westby M, Dobbs S, Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 2005;49:4721-32
   PubMed Web of Science ®Google Scholar
• Berger EA, Murphy PM, Farber JM. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol 1999;17:657-700
   PubMed Web of Science ®Google Scholar
• Rusconi S, Bulgheroni E, Citterio P. Entry and fusion inhibitors of HIV. Expert Opin Ther Pat 2004;14:733-48
   Web of Science ®Google Scholar
• Pease JE, Horuk R. Chemokine receptor antagonists: part 1. Expert Opin Ther Pat 2009;19:39-58
   PubMed Web of Science ®Google Scholar
• Pease JE, Horuk R. Chemokine receptor antagonists: part 2. Expert Opin Ther Pat 2009;19:199-21
   PubMed Web of Science ®Google Scholar
• Yang H, Rotstein DM. Novel CCR5 antagonists for the treatment of HIV infection: a review of compounds patented in 2006 – 2008. Expert Opin Ther Pat 2010;20:325-54
   PubMed Web of Science ®Google Scholar
• Mosley CA, Wilson LJ, Wiseman JM, Recent patents regarding the discovery of small molecule CXCR4 antagonists. Expert Opin Ther Pat 2009;19:23-8
   PubMed Web of Science ®Google Scholar
• Moyle GJ, Wildfire A, Mandalia S, Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. J Infect Dis 2005;191:866-72
   PubMed Web of Science ®Google Scholar
• Vermeire K, Schols D, Bell TW. CD4 down-modulating compounds with potent anti-HIV activity. Curr Pharm Des 2004;10:1795-803
   PubMed Web of Science ®Google Scholar
• Hartley O, Gaertner H, Wilken J, Medicinal chemistry applied to a synthetic protein: development of highly potent HIV entry inhibitors. Proc Natl Acad Sci USA 2004;101:16460-65
   PubMedGoogle Scholar
• Kawamura T, Bruse SE, Abraha A, PSC-RANTES blocks R5 human immunodeficiency virus infection of Langerhans cells isolated from individuals with a variety of CCR5 diplotypes. J Virol 2004;78:7602-9
   PubMed Web of Science ®Google Scholar
• Balzarini J, Van Damme L. Microbicide drug candidates to prevent HIV infection. Lancet 2007;369:787-97
   PubMed Web of Science ®Google Scholar
• Lederman MM, Offord RE, Hartley O. Microbicides and other topical strategies to prevent vaginal transmission of HIV. Nat Rev Immunol 2006;6:371-82
   PubMed Web of Science ®Google Scholar
• Baba M, Nishimura O, Kanzaki N, A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc Natl Acad Sci USA 1999;96:5698-703
   PubMed Web of Science ®Google Scholar
• Seto M, Aikawa K, Miyamoto N, Highly potent and orally active CCR5 antagonists as anti-HIV-1 agents: synthesis and biological activities of 1-benzazocine derivatives containing a sulfoxide moiety. J Med Chem 2006;49:2037-48
   PubMed Web of Science ®Google Scholar
• Takeda Pharmaceutical Co, Ltd. Preparation of N-phenyl-N-[3-(4-benzylpiperidin-1-yl)propyl]urea derivatives as CCR5 antagonists. WO2004026832; 2004
   Google Scholar
• Takeda Pharmaceutical Co, Ltd. Preparation of cyclic amine compounds as chemokine receptor antagonists useful in treatment of AIDS. WO2004026833; 2004
   Google Scholar
• Takeda Pharmaceutical Co, Ltd. Preparation of acrylamide derivatives as CCR antagonists. WO2004069808; 2004
   Google Scholar
• Takeda Pharmaceutical Co, Ltd. Preparation of fused-ring pyridine derivatives, process for producing the same, and use. WO2004069833; 2004
   Google Scholar
• Takeda Pharmaceutical Co, Ltd. Preparation of tricyclic compounds as CCR antagonists for treatment of HIV infection. WO2004069834; 2004
   Google Scholar
• Demarest J, the Aplaviroc Project T. Update on Aplaviroc: an HIV entry inhibitor targeting CCR5. Retrovirology 2005;2:S13
   PubMedGoogle Scholar
• SmithKline Beecham Corp. Substituted heterocyclic compounds as modulators of the CCR5 receptor, and therapeutic use. WO2004010942; 2004
   Google Scholar
• Smithkline Beecham Corp. Preparation of benzanilides as modulators of the CCR5 receptor. WO2004010943; 2004
   Google Scholar
• SmithKline Beecham Corp. Preparation of benzanilides as modulators of the chemokine CCR5 receptor. WO2004011427; 2004
   Google Scholar
• SmithKline Beecham Corp. Preparation of heterocyclylalkyl substituted cyclohexyl compounds as CCR5 antagonists. WO2004054581; 2004
   Google Scholar
• SmithKline Beecham Corp. Preparation of aminoalkylaryl cyclopropyl compounds as CCR5 antagonists. WO2004055010; 2004
   Google Scholar
• SmithKline Beecham Corp. CCR5 antagonists as therapeutic agents. WO2004054974; 2004
   Google Scholar
• SmithKline Beecham Corp. Preparation of indane compounds and analogs as CCR5 antagonists. WO2004055012; 2004
   Google Scholar
• SmithKline Beecham Corp. Preparation of oxazine and morpholine derivatives as CCR5 antagonists. WO2004055011; 2004
   Google Scholar
• SmithKline Beecham Corp. Preparation of pyrrolidine and azetidine compounds as CCR5 antagonists. WO2004055016; 2004
   Google Scholar
• SmithKline Beecham Corp. Preparation of phenyl piperidinyl ureas as CCR5 antagonists useful in treatment and prevention of CCR5-related diseases. WO2009058919; 2009
   Google Scholar
• SmithKline Beecham Corp. Preparation of substituted ureas as CCR5 antagonists. WO2009075960; 2009
   Google Scholar
• SmithKline Beecham Corp. Preparation of piperidinyl pyridyl Ph ureas as CCR5 antagonists useful in treatment and prevention of CCR5-related diseases. WO2009058921; 2009
   Google Scholar
• SmithKline Beecham Corp. Preparation of piperidinyl aryl ureas as CCR5 antagonists useful in treatment and prevention of CCR5-related diseases. WO2009058924; 2009
   Google Scholar
• SmithKline Beecham Corp. CCR5 antagonists as therapeutic agents. WO2009058923; 2009
   Google Scholar
• Pfizer Ltd. Preparation of imidazopyridine substituted tropane derivatives with CCR5 receptor antagonist activity for the treatment of HIV and inflammation. WO2005033107; 2005
   Google Scholar
• Pfizer Ltd. 8-Azabicyclo[3.2.1]octane derivatives with an activity on chemokine CCR5 receptors and their preparation, pharmaceutical compositions and use for treatment of inflammatory diseases and infection caused by HIV and genetically related retroviruses. WO2006067584; 2006
   Google Scholar
• Pfizer Ltd. Preparation of 1,4′-bipiperidinyl carboxamide derivatives as chemokine CCR5 receptor antagonists. WO2006077499; 2006
   Google Scholar
• Pfizer Ltd. Preparation of triazolylpiperidine derivatives for use as CCR5 receptor modulators for treating various diseases. WO2006136917; 2006
   Google Scholar
• Pfizer Ltd. Piperidine derivatives, processes for preparing them, pharmaceutical compositions containing them, and their use as modulators of chemokine CCR5 receptors. WO2007066201; 2007
   Google Scholar
• Pfizer Ltd. Preparation of piperidine derivatives as modulators, especially antagonists, of chemokine CCR5 receptors. WO2007116313; 2007
   Google Scholar
• Pfizer Ltd. Pharmaceuticals. WO2007144720; 2007
   Google Scholar
• Pfizer Ltd. 3-Aminocyclopentanecarboxamide as chemokine receptor modulators. WO2010061329; 2010
   Google Scholar
• Tagat JR, McCombie SW, Nazareno D, Piperazine-based CCR5 antagonists as HIV-1 inhibitors. IV. Discovery of 1-[(4,6-dimethyl-5-pyrimidinyl)carbonyl]- 4-[4-[2-methoxy-1(R)-4-(trifluoromethyl)phenyl]ethyl-3(S)-methyl-1-piperaz inyl]- 4-methylpiperidine (Sch-417690/Sch-D), a potent, highly selective, and orally bioavailable CCR5 antagonist. J Med Chem 2004;47:2405-8
   PubMed Web of Science ®Google Scholar
• Schering Corp. A preparation of (piperidinyl-N-carboxy)pyrimidine derivatives, useful as CCR5 antagonists. WO2004056770; 2004
   Google Scholar
• Schering Corp. Piperazine derivatives and their preparation, pharmaceutical compositions and use as CCR5 antagonists for treatment of human immunodeficiency virus or inflammatory diseases. US2006105964; 2006
   Google Scholar
• Schering Corp. Preparation of piperidinyl piperazine derivatives useful as inhibitors of chemokine receptors. WO2006091692; 2006
   Google Scholar
• Schering Corp. CCR5 antagonists useful for treating HIV. US2007203149; 2007
   Google Scholar
• Schering Corp. Piperazine derivatives useful as CCR5 antagonists. WO2007050375; 2007
   Google Scholar
• Schering Corp. Quinoline amide derivatives as CCR5 antagonists. WO2004113323; 2004
   Google Scholar
• Schering Corp. Bipiperidinyl derivatives useful as inhibitors of chemokine receptors. WO2005042517; 2005
   Google Scholar
• Schering Corp. Substituted quinoline CCR5 receptor antagonists. WO2004002960; 2004
   Google Scholar
• Schering Corp. Benzylether amine compounds useful as CCR5 antagonists. US20050101644; 2005
   Google Scholar
• Schering Corp. Composition comprising a combination of CCR5 and CXCR4 antagonists. US2007123538; 2007
   Google Scholar
• Schering Corp. CCR5 antagonists as prophylactics for preventing HIV infection and methods of inhibiting transmission of same. WO2009111218; 2009
   Google Scholar
• Schering Corp. Piperazine-based CCR5 antagonist tablet dosage form. WO2009134637; 2009
   Google Scholar
• Roche, Inc. Novel Biaryl derivatives. US2009048238; 2009
   Google Scholar
• Roche, Inc. Novel heterocyclyl compounds. WO2009010429; 2009
   Google Scholar
• Roche, Inc. New pyrazole derivatives. WO2009013211; 2009
   Google Scholar
• Roche, Inc. Novel heteroaryl carboxamide derivatives. WO2009153182; 2009
   Google Scholar
• Roche, Inc. Heterocyclic antiviral compounds. WO2009013171; 2009
   Google Scholar
• Roche, Inc. Preparation of piperidinylspiroundecanones as chemokine CCR5 receptor modulators. WO2009135788; 2009
   Google Scholar
• Roche, Inc. Preparation of piperidinyl 3,9-diazaspiro[5.5]undecanes as antiviral agents. WO2009037168; 2009
   Google Scholar
• Hale JJ, Budhu RJ, Mills SG, 1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 1: discovery of the pyrrolidine scaffold and determination of its stereochemical requirements. Bioorg Med Chem Lett 2001;11:1437-40
   PubMed Web of Science ®Google Scholar
• Merck & Co., Inc4-(spiropiperidinyl)methyl substituted pyrrolidines as modulators of chemokine receptor activity. WO2004058763; 2004
   Google Scholar
• Incyte's Product Pipeline. 2010. Available from: http://www.incyte.com/drugs_product_pipeline.html [Cited 17 November 2010]
   Google Scholar
• Xue C-B, Chen L, Cao G, Discovery of INCB9471, a potent, selective, and orally bioavailable CCR5 antagonist with potent anti-HIV-1 activity. ACS Med Chem Lett 2010: DOI:10.1021/ml1001536
   Google Scholar
• Incyte Corp. Piperazinylpiperidine derivatives as chemokine receptor antagonists. US2005261310; 2005
   Google Scholar
• Incyte Corp. Preparation of 3-aminocyclopentanecarboxamides as modulators of chemokine receptors. WO2007072201; 2007
   Google Scholar
• Incyte Corp. 3-Aminocyclopentanecarboxamides as modulators of chemokine receptors WO2006004741; 2006
   Google Scholar
• Incyte Corp. Combination therapy for human immunodeficiency virus infection WO2008030853; 2008
   Google Scholar
• Incyte Corp. Pentafluorosulfur substituted piperazinylpiperidines as CCR5 chemokine receptor antagonists. WO2009012259; 2009
   Google Scholar
• AstraZeneca AB. Preparation of piperidine and 8-azabicyclo[3.2.1]octane derivatives as modulators of chemokine receptor CCR5. WO2006001752; 2006
   Google Scholar
• AstraZeneca AB. Preparation of piperidine derivatives as CCR5 modulators. WO2006001751; 2006
   Google Scholar
• AstraZeneca AB. Preparation of N-(4-piperidinyl) amide compounds as chemokine receptor CCR5 modulators. WO2004018425; 2004
   Google Scholar
• Astrazeneca AB. A preparation of novel piperidine derivatives as modulators of chemokine receptor CCR5. WO2004056773; 2004
   Google Scholar
• AstraZeneca AB. Process for the preparation of N-(4-piperidinyl)-Nethylphenylacetamides from N-Boc-4-oxopiperidine. WO2006064221; 2006
   Google Scholar
• AstraZeneca AB. Preparation of 4-{(1R,3R)-1-(3,5-difluorophenyl)-3-[4-(3-ethyl-5-isopropyl-4H-1,2,4-triazol-4-yl)piperidin-1-yl]butyl}-1-(methylsulfonyl)piperidine for use in the treatment of CCR5 mediated diseases. US20080139613; 2008
   Google Scholar
• AstraZeneca AB. Preparation of 4-[3-(1,1-difluoroethyl)-5-methyl-4H-1,2,4-triazol-4-yl]-1-{(1R,3R)-3-(3,5-difluorophenyl)-1-methyl-3-[1-(methylsulfonyl)piperidin-4-yl]propyl}piperidine for the treatment of CCR5 disease. US20080139612; 2008
   Google Scholar
• Virochem Pharma, Inc. Preparation of spirotropane compounds and therapeutic use as modulators of chemokine receptor activity. WO2006060919; 2006
   Google Scholar
• Virochem Pharma, Inc. Preparation of spirotropane compounds and methods for the modulation of chemokine receptor activity to block cellular entry of HIV. WO2006060918; 2006
   Google Scholar
• Virochem Pharma, Inc. Spirotropane compounds, processes for preparing them, pharmaceutical compositions containing them, and their use as modulators of CCR5 chemokine receptors. WO2007143847; 2007
   Google Scholar
• ViroChem Pharma. Preparation of novel spiropiperidine compounds for the modulation of chemokine receptor activity. WO2007065256; 2007
   Google Scholar
• Virochem Pharma, Inc. Preparation of spiro compounds for the modulation of chemokine receptor activity. WO2005007656; 2005
   Google Scholar
• Virochem Pharma, Inc. Preparation of pyrrolidinylmethyldiazaspirodecanones and related compounds as modulators of CCR5 chemokine receptor activity. WO2005023809; 2005
   Google Scholar
• Virochem Pharma, Inc. Preparation of spirohydantoins as modulators of chemokine receptor activity. WO2005023810; 2005
   Google Scholar
• Virochem Pharma, Inc. Preparation of spirohydantoins for the modulation of chemokine receptor activity. WO2006000096; 2006
   Google Scholar
• Anormed, Inc. Preparation of piperidines as chemokine receptor, particularly CCR5, modulators for treatment of inflammatory and autoimmune diseases. WO2005059107; 2005
   Google Scholar
• Anormed, Inc. Preparation of acylaminoalkylpiperidinamines as CCR5 chemokine receptor ligands. US20050277668; 2005
   Google Scholar
• Anormed, Inc. Preparation of piperidinyl substituted ureas and amides as chemokine receptor binding compounds. WO2006138350; 2006
   Google Scholar
• Anormed, Inc. Substituted imidazolidinones and related compounds as chemokine receptor binding compounds and their preparation, pharmaceutical compositions and use in the treatment of infection of target cells by human immunodeficiency virus. WO2007022371; 2007
   Google Scholar
• Genzyme Corp. Preparation of piperidine derivatives as modulators of chemokine receptor in particular CCR5 receptor. WO2008070758; 2008
   Google Scholar
• Anormed, Inc. Preparation of (8S)-[N-(1H-benzimidazole-2-ylmethyl)-N-5,6,7,8-tetrahydroquinolin-8-yl]-1,4-butanediamine salts as modulators of chemokine receptors. US2006069122; 2006
   Google Scholar
• Euroscreen programs overview. 2010. Available from: http://www.euroscreen.com/index.php/Programs-Overview.html [Cited 17 November 2010]
   Google Scholar
• Euroscreen. Preparation of piperidine derivatives as agonists of chemokine receptor activity. WO2009010478; 2009
   Google Scholar
• Euroscreen. Preparation of heterocyclic methylene piperidine derivatives as therapeutic chemokine receptor modulators. WO2009010479; 2009
   Google Scholar
• Euroscreen. Preparation of piperidine-4-acetic acid derivatives as chemokine receptor agonists. WO2009010477; 2009
   Google Scholar
• Euroscreen. Preparation of diphenylaminoethylpiperidinecarboxylic acid benzylamide derivatives and analogs as CCR5 agonists. WO2009010480; 2009
   Google Scholar
• Ono Pharmaceuticals. Preparation of pyridinyl benzenesulfonylamide derivatives as chemokine receptor antagonist. WO2005023771; 2005
   Google Scholar
• Ono Pharmaceuticals. CCR5 activators comprising derivatives of 1,4,9-triazaspiro(5.5)undecane for CCR5 desensitization and for therapy of allergy, inflammation, autoimmune or immune disease, metastasis and HIV infection. JP2004359641; 2004
   Google Scholar
• Ono Pharmaceuticals. Preparation of triazaspiro[5.5]undecane derivatives as chemokine receptor CCR5 antagonists and drugs comprising the same as the active ingredients. WO2004026873; 2004
   Google Scholar
• Ono Pharmaceuticals. Preparation of triazaspiroalkanedione derivatives as chemokine receptor antagonists. WO2004094424; 2004
   Google Scholar
• Ono Pharmaceuticals. Preparation of spiropiperidine compounds as chemokine receptor antagonists and medicinal use thereof. WO2004092169; 2004
   Google Scholar
• Ono Pharmaceuticals. Preparation of N-[(piperidinyl)benzyl]benzamides as chemokine receptor antagonists. WO2004092136; 2004
   Google Scholar
• Ono Pharmaceuticals. Preparation of nitrogenated heterocyclic derivatives as antagonists of chemokine receptor 5 (CCR5). WO2007105637; 2007
   Google Scholar
• Ono Pharmaceuticals. Preparation of N-containing heterocyclic compounds as CCR5 antagonists. WO2006030925; 2006
   Google Scholar
• Ono Pharmaceuticals. Preparation of nitrogen-containing heterocyclic derivatives as chemokine receptor CCR5 antagonists and drugs containing the same as the active ingredient. WO2004080966; 2004
   Google Scholar
• Kemia. Preparation of aryl bicyclo and spiro compounds as therapeutic modulators of CCR-5 activity. WO2006130426; 2006
   Google Scholar
• Auspex Pharmaceuticals. 8-Azabicyclo[3.2.1]octane-base compounds, preparation and utility of CCR5 inhibitors and use in the treatment of infections. US2008146605; 2008
   Google Scholar
• Concert Pharmaceuticals. Preparation of deuterated triazolyl tropane derivatives as CCR5 receptor inhibitors. WO2008063600; 2008
   Google Scholar
• Concert Pharmaceuticals. Piperazine derivatives. WO2009128947; 2009
   Google Scholar
• Concert Pharmaceuticals. Preparation of deuterated vicriviroc derivatives as CCR5 chemokine receptor antagonists. US20100120786; 2010
   Google Scholar
• Novartis. Preparation of 1H-indole-2-carboxylic acid N-(piperidin-4-yl)amides and related derivatives as chemokine receptor, particularly CCR2 and CCR5 antagonists. WO2005077932; 2005
   Google Scholar
• Institute of pharmacology and toxicology, academy of military medical sciences. Preparation of benzocycloheptene derivatives as CCR5 inhibitors. CN101481323; 2009
   Google Scholar
• Avance Pharma, Inc. CCR5 receptor antagonists for treatment of AIDS. CA2522632; 2007
   Google Scholar
• Tachibana K, Hirota S, Iizasa H, The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature 1998;393:591-94
   PubMed Web of Science ®Google Scholar
• Wilkin TJ, Su Z, Kuritzkes DR, HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. Clin Infect Dis 2007;44:591-5
   PubMed Web of Science ®Google Scholar
• Doranz BJ, Filion LG, Diaz-Mitoma F, Safe use of the CXCR4 inhibitor ALX40-4C in humans. AIDS Res Hum Retroviruses 2001;17:475-86
   PubMed Web of Science ®Google Scholar
• Tamamura H, Murakami T, Masuda M, Structure-activity relationships of an anti-HIV peptide, T22. Biochem Biophys Res Commun 1994;205:1729-35
   PubMedGoogle Scholar
• Tamamura H, Xu Y, Hattori T, A low-molecular-weight inhibitor against the chemokine receptor CXCR4: a strong anti-HIV peptide T140. Biochem Biophys Res Commun 1998;253:877-82
   PubMed Web of Science ®Google Scholar
• Hendrix CW, Collier AC, Lederman MM, Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. J Acquir Immune Defic Syndr 2004;37:1253-62
   PubMed Web of Science ®Google Scholar
• Hatse S, Princen K, De Clercq E, AMD3465, a monomacrocyclic CXCR4 antagonist and potent HIV entry inhibitor. Biochem Pharmacol 2005;70:752-61
   PubMed Web of Science ®Google Scholar
• Stone ND, Dunaway SB, Flexner C, Multiple-dose escalation study of the safety, pharmacokinetics, and biologic activity of oral AMD070, a selective CXCR4 receptor inhibitor, in human subjects. Antimicrob Agents Chemother 2007;51:2351-58
   PubMed Web of Science ®Google Scholar
• Anormed, Inc. Preparation of cis-2,6-di(pyridyl)piperidines and other cis-di(heteroaryl)-substituted azaheterocycles as binding agents for CXCR4 and other chemokine receptors for treatment of HIV, rheumatoid arthritis, and other diseases and for stimulating progenitor and stem. WO2004093817; 2004
   Google Scholar
• Ono Pharmaceutical Co. Preparation of nitrogen-containing heterocyclic compounds as CXCR4 regulators. WO2004052862; 2004
   Google Scholar
• Ono Pharmaceutical Co. Preparation of basic group-containing heterocyclic compounds as CXCR4 antagonists. WO2006022454; 2006
   Google Scholar
• Ono Pharmaceutical Co. Preparation of 2-aminopyrimidine compounds as CXCR4 antagonists. WO2006090853; 2006
   Google Scholar
• Ono Pharmaceutical Co. Preparation of diazacycloalkane-containing N,N-bis(1H-imidazol-2-ylmethyl)aminesand related N,N-bis(heteroarylmethyl)amines as antagonists of chemokine receptor CXCR4. WO2007058322; 2007
   Google Scholar
• Ono Pharmaceutical Co. Preparation of heterocycle compounds having (un)protected acidic group as CXCR4 antagonists. WO2007132846; 2007
   Google Scholar
• SmithKline Beecham Corp. Preparation of heteroarylmethyl substituted octahydro-1,10-phenanthrolines and analogs for treating diseases modulated by a chemokine receptor (CXCR4). WO2006096444; 2006
   Google Scholar
• Smithkline Beecham Corp. Pyranopyridines and oxepinopyridines as protectants from HIV infection, their preparation, pharmaceutical compositions, and use in therapy. WO2007008539; 2007
   Google Scholar
• SmithKline Beecham Corp. Imidazo[1,2-a]pyridine compounds as chemokine receptor ligands and their preparation, pharmaceutical compositions and use in the treatment of HIV infection. WO2007027999; 2007
   Google Scholar
• SmithKline Beecham Corp. Preparation of imidazo[1,2-a]pyridine compounds useful in the treatment of HIV infection and other chemokine receptor-mediated diseases. WO2007087549; 2007
   Google Scholar
• Anormed, Inc. Preparation of chemokine receptor binding (benzimidazol-2-ylmethyl)(5,6,7,8-tetrahydroquinolin-8-yl)amines and related heterocyclic compounds with enhanced efficacy against AIDS and other disorders. US2004019058; 2004
   Google Scholar
• SmithKline Beecham Corp. Preparation of 8-(imidazol-2-ylmethylamino)-5,6,7,8-tetrahydroquinolines that bind to chemokine receptors for use against HIV and other disorders. WO2006020415; 2006
   Google Scholar
• SmithKline Beecham Corp. Preparation of (quinolinylaminoalkyl)-benzimidazole derivatives as chemokine receptor ligands with anti-HIV activity. WO2006023400; 2006
   Google Scholar
• Smithkline Beecham Corp. Preparation of imidazo[1,2-a]pyridine derivatives as chemokine receptor ligands with anti-HIV activity. WO2006026703; 2006
   Google Scholar
• SmithKline Beecham Corp. Preparation of N-[(imidazo[1,2-a]pyridin-2-yl)methyl]-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-amines that bind to chemokine receptors for use against HIV and other disorders. WO2006076131; 2006
   Google Scholar
• SmithKline Beecham Corp. Aminotetrahydroquinolines as cytoprotectants from HIV infection, their preparation, pharmaceutical compositions, and use in therapy. WO2006036816; 2006
   Google Scholar